

CLAIMS

We claim:

- 5 1) A method for reducing or eliminating a
 decrease in neurosensory retinal function
 following laser treatment of chorodial
 neovascularization (CNV) while maintaining
10 the vascular occlusion therapeutic effect of
 such therapy, the method comprising the
 steps: a) administering to a mammal having
 a CNV a therapeutically effective amount of
 an alpha receptor agonist, b) subjecting
15 said mammal to laser irradiation of the
 retinal locus of the CNV; wherein the amount
 of neurosensory retinal function following
 steps a) and b) is greater than when said
 mammal is subjected to step b) without step
20 a) .
- 2) The method of claim 1 wherein the alpha
 adrenergic receptor agonist is an alpha 2
 selective agonist.
- 25 3) The method of claim 2 wherein the alpha
 adrenergic receptor agonist is selected from
 the group consisting of brinoinidine,
 clonidine, and para-aminoclonidine.
- 30 4) The method of claim 3 in which the alpha
 adrenergic receptor agonist is brimonidine.

- 5
- 6) The method of claim 2 wherein the alpha 2 selective agonist is an alpha 2B and/or 2C selective agonist.
- 10
- 7) The method of claim 3 wherein the alpha 2 selective agonist is an alpha 2B selective agonist.
- 15
- 8) The method of claim 6 in which the alpha 2B selective agonist is selected from the group consisting of AGN 960, AGN 795 and AGN 923.
- 20
- 9) The method of claim 7 in which the alpha 2B selective agonist is AGN 960.
- 25
- 10) The method of claim 7 in which the alpha 2B selective agonist is AGN 795.
- 30
- 11) The method of claim 7 in which the alpha 2B selective agonist is AGN 923.
- 12) The method of claim 4 wherein the alpha 2 selective agonist is an alpha 2B specific agonist.
- 13) The method of claim 1 wherein prior to step b) said method comprises: administering to said patient a therapeutically effective amount of a photoactive agent in a manner

such that said photoactive agent is present
in the CNV during step b).

- 5 13) A method of protecting ocular neural tissue
from damage caused by electromagnetic
irradiation of the retina comprising
delivering to a patient's ocular neural
tissue an amount of a neuroprotectant
compound effective to protect a plurality of
10 ocular neurons from cell death as compared
to ocular neuron cell death following such
irradiation observed in the absence of the
administration of said neuroprotectant.
- 15 14) The method of claim 13 wherein said
electromagnetic irradiation is laser
irradiation.
- 20 15) The method of claim 13 wherein said
neuroprotectant compound is an alpha
adrenergic agonist.
- 25 16) The method of claim 13 wherein said alpha
adrenergic agonist is an alpha 2 selective
agonist.
- 30 17) The method of claim 16 wherein said alpha 2
selective agonist is selected from the group
consisting of brimonidine, clonidine and
para-aminoclonidine.

03969748-1001
TOTAL 3728550

- 18) The method of claim 17 wherein said compound
is brimonidine.
- 19) The method of claim 13 wherein said alpha
adrenergic receptor agonist is an alpha 2B
and/or alpha 2C selective agonist.
- 20) The method of claim 19 wherein said alpha 2B
and/or alpha 2C selective agonist is
selected from the group consisting of AGN
960, AGN 795 and AGN 923.
- 21) The method of claim 20 in which the alpha 2B
selective agonist is AGN 960.
- 22) The method of claim 20 in which the alpha 2B
selective agonist is AGN 795.
- 23) The method of claim 20 in which the alpha 2B
selective agonist is AGN 923.
- 24) The method of claim 13 wherein said
neuroprotectant compound is administered at
a time sufficiently before said
electromagnetic irradiation to permit
localization within ocular tissue prior to
said treatment.
- 25) The method of claim 13 wherein said
neuroprotectant compound is administered
following said electromagnetic irradiation.